CSL Limited Financial Update – 2026

Market Sentiment and Analyst Coverage

On 3 February 2026, Citi’s research analyst Laura Sutcliffe reaffirmed a Buy recommendation for CSL Limited (ticker CMXHF), citing the company’s robust pipeline and recent insider buying activity. Sutcliffe set a price target of A$225.00 and highlighted the firm’s position within the healthcare sector. In a separate note issued on 27 January 2026, Morgan Stanley’s David Bailey also issued a Buy rating, reinforcing analyst confidence.

TipRanks reported that, despite the overall positive sentiment, the platform downgraded CSL to a Hold on 3 February, citing short‑term volatility concerns. The downgrade followed a broader market review of the S&P/ASX 50 ETF managed by State Street Global Advisors, which included CSL with 439 shares in its index basket. The ETF’s creation unit for 3 February 2026 was valued at $1,880,430.00, underscoring the liquidity and institutional interest in CSL shares.

Half‑Year Financial Results Announcement

CSL Limited scheduled the release of its 2026 Half‑Year (HY26) financial results for 11 February 2026. A live briefing for investors and analysts will be held at 10:00 AM AEDT on the same day and will be webcast through the company’s website. All results materials will be made available in the ‘Investors’ section of the site, with a recording posted the same day.

Company Profile

CSL Limited is a biotechnology firm headquartered in Parkville, Australia. It specializes in the development, manufacturing, and marketing of human plasma‑derived pharmaceuticals and diagnostic products. The product portfolio includes pediatric and adult vaccines, treatments for infections, pain management, skin disorders, antivenoms, anticoagulants, and immunoglobulins. The company is listed on the ASX All Markets and trades under the ticker CSL.

Key Financial Metrics (as of 29 January 2026)

  • Market Capitalisation: A$88,016,166,912
  • Price‑to‑Earnings Ratio: 20.45
  • Recent Closing Price: A$181.42
  • 52‑Week High (02 Feb 2025): A$277.18
  • 52‑Week Low (28 Oct 2025): A$168.00

These figures reflect a firm with substantial market value and a healthy valuation relative to its earnings, supporting the current analyst consensus and the price target set by Citi.

Summary

CSL Limited remains a focal point for investors in the healthcare biotechnology sector. Analyst coverage on 3 February 2026 confirms a bullish stance with a target of A$225.00, while institutional inclusion in the S&P/ASX 50 ETF highlights ongoing demand. The forthcoming half‑year results, due on 11 February 2026, will provide further insight into the company’s performance and strategic direction.